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Automated, high-throughput serum glycoprofiling
platform†‡
H. Stöckmann,§a R. O’Flaherty,§a B. Adamczyk,b R. Saldovaa and P. M. Rudd*a
Complex carbohydrates are rapidly becoming excellent biomarker candidates because of their high
sensitivity to pathological changes. However, the discovery of clinical glycobiomarkers has been slow,
due to the scarcity of high-throughput glycoanalytical workflows that allow rapid glycoprofiling of large
clinical sample sets. To generate high-quality quantitative glycomics data in a high-throughput fashion, we
have developed a robotized platform for rapid serum-based N-glycan sample preparation. The sample
preparation workflow features a fully automated, rapid glycoprotein denaturation followed by sequential
enzymatic glycan release, glycan purification on solid-supported hydrazide and fluorescent labelling.
This allows accurate glycan quantitation by ultra-high performance liquid chromatography (UPLC). The
sample preparation workflow was automated using an eight-channel Hamilton Robotics liquid handling
workstation, allowing the preparation of almost 100 samples in 14 hours with excellent reproducibility
and thus should greatly facilitate serum-based glyco-biomarker discovery.
Insight, innovation, integration
It is well recognized that glycans affect cellular function in biological system; consequently glycoprofiling can be useful for disease pathophysiology and to
identify biomarkers for various diseases. Serum contains a high abundance of glycans and whole serum glycomic approaches have been used in disease
diagnosis studies. We have developed a high-throughput robotic platform for whole serum N-glycan analysis which allows accurate glycan quantification by
ultra-high performance liquid chromatography. The method offers a facile and rapid preparation of almost 100 samples in 14 hours with excellent
reproducibility. Diagnostic information about disease progression and biological mechanism can be extracted from the data and should expedite the
emergence of novel biomarkers. This technique can also serve as a complimentary approach to proteomic research.
Introduction
The majority of all human proteins are glycosylated, and altera-
tions in glycosylation impact numerous physiological and patho-
logical processes.1–3 Attached glycans significantly affect protein
function and pathophysiology but they are not directly encoded
by genes, and the regulation of glycan expression is poorly
understood. Recently, large-scale glycoprofiling studies have
been combined with human genome-wide association studies
(GWAS) to examine the regulation of glycan expression in
human populations.4–6 For instance, the combination of GWAS
and high-throughput glycomics analysis of more than 2500
individuals showed that common variants in the Hepatocyte
Nuclear Factor a (HNFa) and fucosyl-transferase genes influ-
ence N-glycan levels in human plasma, thereby revealing a new
role for HNFa as a master transcriptional regulator of multiple
stages in the fucosylation process.5 However, future GWAS will
require the processing of substantially larger sample sets in a
rapid and cost-effective fashion.
N-glycan profiling can be enabled by several analytical
approaches, including separation chromatography such as
reverse phase chromatography, hydrophilic interaction chromato-
graphy and capillary electrophoresis and these techniques been
reviewed extensively.7,8 Matrix-assisted laser desorption/ionization
(MALDI) time-of-fight (TOF) mass spectrometry (MS) has also
been comprehensively utilised; however problems associated
with stability of the sialylated glycan species, which is often
overcome by permethylation reactions hinders its high through-
put capabilities.9 One of the latest advances in the field of glycan
profiling is the implementation of HILIC UPLC, exhibiting
increased separation efficiency compared to HPLC for increased
speed and throughput.10,11
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We have recently reported the first low-cost, high-throughput
automated glycan sample preparation platform, which allows
accurate glycan quantification of glycans derived from affinity
purified proteins such as Immunoglobulin G (IgG).12 Although
glycoprofiling of individual glycoproteins is extremely useful for
understanding disease pathophysiology and biomarker discovery,
the serum glycome encodes much more biological information
than glycans derived from individual serum glycoproteins. Thus,
whole serum glycomics has been used as a valuable comple-
mentary tool in glycobiology research. Our laboratory had pre-
viously developed a HPLC-based analysis of serum N-glycans on
a 96-well plate and breast cancer patients have been identified
using UPLC-based analysis.13 Furthermore, N-glycan abnormalities
have been found in children with galactosemia, which yielded a
better understanding of the pathophysiology of the disease and
paves the way for new treatment strategies.14 Moreover, glyco-
sylation changes in the serum of inflammatory arthritis
patients on anti-TNF therapy were found to be associated with
a decrease in inflammatory processes and reflect the effect of
anti-TNF on the immune system.15 Although the 96-well glycan
sample preparation platform has been very useful in many
glycomics studies, the method is labour-intensive and difficult
to automate, which is often an industry expectation. Thus, we
adapted our existing robotized glycomics platform for whole
serum glycan sample preparation and compared this with the
existing 96-well manual method.12,16
Experimental
All chemical reagents and solvents were purchased from Sigma-
Aldrich (St. Louis, MO). Solid-supported hydrazide was obtained
from Fisher Scientific (Waltham, MA). Solvinert filter plates were
from Merck-Millipore (Billerica, MA) and Acroprep filter plates
from Pall (Port Washington, NY). Samples were prepared on a
Hamilton Robotics StarLet liquid handling platform (Reno, NV).
The instrument is equipped with 8 software-controlled pipettes,
a vacuum manifold and an automated heater shaker. Samples
were analyzed on a Waters Acquity H-Class UPLC instrument
(Milford, MA). The sample preparation workflow was implemented
as a robotic program on Hamilton Robotics Venus One software.
Glycoprotein denaturation, release and solid phase extraction can
be performed on up to 96 samples in parallel.
Native human serum (NHS) samples
A total of 100 adult serum samples from apparently healthy
male and female adult blood donors were pooled and used as a
source of serum glycoproteins for subsequent glycan analysis
(courtesy of the UK Blood Transfusion Service).
Glycoprotein denaturation and glycan release
Denaturation buffer (55 mL per well, 100 mM ammonium
bicarbonate, 12 mM dithiothreitol) was dispensed into a 96-well
V-bottom PP plate (Greiner Bio-One Cat.No.: 651201) containing
serum (5 mL per well), which was placed on a robotic heater shaker
and fully covered and insulated with an anti-evaporation lid.
This assembly was incubated at 65 1C with agitation at 700 rpm
for 20 min. After cooling to room temperature for 15 min, an
iodoacetamide solution (120 mM, 10 mL per well) was added,
the multiwell plate was covered with an anti-evaporation lid
and incubated at room temperature with agitation at 700 rpm
for 30 min. A trypsin solution (10 mL of a 40 000 U mL1
solution per well) was added, the plate was sealed with adhesive
aluminium film, placed on the robotic heater shaker and fully
covered with an anti-evaporation lid. Incubation was performed
at 40 1C with agitation at 700 rpm for 120 min. Next, the temperature
was increased to 105 1C and incubation was continued for 10 min.
The plate was left to cool to room temperature, briefly spun and
the seal removed. PNGase F (Prozyme r Glyco N-Glycanase r,
code GKE-5006D, 10 mL per well, 0.5 mU in 1 M ammonium
bicarbonate, pH 8.0) was added and the plate was insulated with
an anti-evaporation lid and incubated at 40 1C with agitation at
700 rpm for 120 min.
Hydrazide-mediated glycan clean-up
Hydrazide-assisted glycan clean-up and glycan labelling was
performed essentially as previously described:12 Each well of a
96-well chemically inert filter plate (Millipore Solvinert, hydro-
phobic polytetrafluoroethylene membrane, 0.45 mm pore size)
was washed with 100 mL methanol (MeOH). Ultralink hydrazide
resin (40 mL of a suspension in water, ThermoScientific) was
dispensed to each well. The resin was sequentially washed with
MeOH, H2O and acetonitrile (MeCN) and the plate was placed
on a heater (70 1C, 10 min) to seal the membranes. 180 mL
MeCN/acetic acid (98 : 2) was added to the resin, followed by
20 mL of the glycan solution. The filter plate was incubated with
shaking at 700 rpm at 70 1C for 45 min. 50 mL MeCN/acetic acid
(98 : 2) were added and shaking was continued at the same
temperature for 10 min to disrupt resin aggregates. The resin
was washed sequentially with MeOH, guanidine (2 M), H2O,
triethylamine/MeOH (1 : 99) and MeOH. Fresh MeOH (180 mL)
and acetic anhydride (20 mL) were added and the plate was
incubated for 10 min with agitation at 700 rpm. Excess reagent
was removed by filtration and the resins were washed sequen-
tially with MeOH, H2O and MeCN. Acetic acid/MeCN (2 : 98,
180 mL) and H2O (20 mL) were sequentially added and the plate
was incubated at 70 1C with agitation at 700 rpm for 60 min.
Fluorescent labelling mix (50 mL, 350 mM 2-aminobenzamide,
1 M sodium cyanoborohydride in acetic acid/dimethyl sulfoxide
(30 : 70)) was dispensed into each well and the plate was
incubated at 70 1C with agitation at 700 rpm for 120 min.
Glycan solid phase extraction
The labelling reaction was quenched by the addition of 200 mL
MeCN/H2O (95 : 5). The suspension was transferred to a 2 mL
collection plate, the beads were left to settle, 200 mL of the
supernatant was aspirated and dispensed back into the filter
plate. After extensive mixing the suspension was transferred
back into the collection plate. This cycle was repeated once
more to ensure a quantitative transfer of the resins.
HyperSep Diol SPE cartridges (Thermo Scientific) were
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MeCN/H2O (95 : 5). Next, the supernatants of the quenched
reaction mixtures without the beads were transferred onto
the SPE cartridges. 10 min incubation typically led to complete
drainage of the solvent by gravity. The SPE cartridges were
washed three times with 700 mL MeCN/H2O (95 : 5). A collection
plate was placed inside the robotic vacuum manifold and the
SPE cartridges were washed twice with 200 mL H2O/MeCN
(80 : 20), with an intermittent incubation period of 10 min. The
samples were concentrated to dryness in a vacuum evaporator
(typically 4–6 hour for 96 samples). The samples were dissolved
in 30 mL MeCN/H2O (70 : 30) and filtered (Pall Acroprep GHP
membrane, 0.45 mm pore size). A 10 mL aliquot of the filtrate was
analyzed by UPLC.
Ultra performance liquid chromatography (UPLC)
2-AB derivatized N-glycans were separated by UPLC with fluores-
cence detection on a Waters Acquity UPLC H-Class instrument
consisting of a binary solvent manager, sample manager and
fluorescence detector under the control of Empower 3 chroma-
tography workstation software (Waters, Milford, MA, USA). The
HILIC separations were performed using a Waters Ethylene
Bridged Hybrid (BEH) Glycan column, 150  2.1 mm i.d.
186004742, 1.7 mm BEH particles, with 50 mM ammonium for-
mate, pH 4.4, as solvent A and MeCN as solvent B. The separa-
tion was performed using a linear gradient of 70–53% MeCN at
0.56 mL min1 in 30 min. An injection volume of 10 mL sample
prepared in 70% v/v MeCN was used throughout. Samples were
maintained at 5 1C prior to injection and the separation
temperature was 40 1C. The fluorescence detection excitation/
emission wavelengths were lex = 330 nm and lem = 420 nm,
respectively. The system was calibrated using an external
standard of hydrolyzed and 2AB-labelled glucose oligomers to
create a dextran ladder, as described previously.16 A fifth-order
polynomial distribution curve was fitted to the dextran ladder
to assign glucose unit (GU) values from retention times (using
Empower software from Waters).
Results and discussion
The most widely used method for releasing N-glycans from
glycoprotein mixtures is in-solution release with PNGaseF.17,18
To accurately quantify released glycans, they are typically
labelled with fluorophores via reductive amination. However,
whole serum consists of a complex mixture of proteins, salts
and lipids, all of which can interfere with the fluorescent
labelling reaction, and the reductive amination in such com-
plex biological matrices typically results in side-products and
poor reaction conversion. This, in turn, adversely impacts assay
performance, e.g. specificity, accuracy, precision, and limit
of quantitation. Although specific guidelines have not yet
been defined for qualifying an analytical method for glycan-
biomarker discovery, it is important that biomarker assays
demonstrate acceptable method performance. To avoid pro-
blems arising from the presence of contaminants in a sample,
an important step has been the immobilization of glycoproteins
to allow the removal of buffers, matrix components, and
the reagents used to denature, reduce, and alkylate the glyco-
proteins. Protein immobilization has been accomplished
by trapping glycoprotein samples in polyacrylamide gel pieces16
or immobilizing glycoproteins onto PVDF membranes.19
When using membranes for immobilization, it is important
to ensure, especially for mixtures of glycoproteins, that the
binding is non-selective because in practice it is difficult to
achieve quantitative binding of the analyte. Trapping glyco-
proteins in polyacrylamide gel pieces, although conventionally
a reliable technique is difficult to automate on liquid handling
robotic workstations and hence relies on manual sample
processing.
Our recently published automated method for antibody
glycoprofiling is a fully integrated platform that combines
glycoprotein affinity purification, protein denaturation, enzy-
matic glycan release, hydrazide-mediated glycan enrichment,
fluorescent glycan labelling and sample clean-up.12 To achieve
robust glycan fluorescence labelling and reproducible quanti-
fication, glycans are captured on solid supports, followed by the
removal of contaminants prior to glycan fluorescence labelling.
Nishimura et al. pioneered a method to capture released glycans
on custom made solid supported hydrazide.17,20 In the present
paper we investigated whether UltraLink hydrazide resin a
complex biological matrix, can be used to isolate glycans from
native human serum.
This glycomic approach can then assist in differential
diagnosis of diseases such as cancers and autoimmune dis-
eases in a high-throughput fashion and can give valuable
biological insights into the mechanism of the diseases. The
analysis of glycoproteins can be crucial to the pharmaceutical
industry; variations of N-glycan structures between glycoforms
of erythropoietin (EPO), a glycoprotein hormone, were found to
be linked to biological activities of the pharmaceutical agents.21
Moreover, we created a robust robotic program with automatic
error recovery to automate the entire serum glycomics workflow
for fast efficient analysis (Fig. 1). First, serum samples are
denatured and trypsinized in a 96-well plate. Trypsinization
was found to be important to circumvent aggregation of the
UltraLink solid supports later in the protocol. Next, glycans
are enzymatically released and reacted with solid-supported
hydrazides to form hydrazones, capturing glycans covalently on
solid supports. Contaminants such as excess reagents and
buffer salts are removed by simple filtration. Subsequently,
glycans are released by acid catalysis in the presence of water.
The reaction solvent evaporates during glycan release and
the dry glycans, which are non-covalently bound to the solid
supports at this stage, and are fluorescently labelled by reduc-
tive amination with 2-aminobenzamide (Fig. 2).
The following protocol was efficiently programmed on a
Hamilton StarLet robot (Fig. 3A). The workstation is software-
controlled and was equipped with pipette tip racks, plate
carriers, reagent reservoirs, a software-controlled vacuum mani-
fold (Fig. 3B), a plate transport tool to move multiwell plates
between positions and operate the vacuum manifold (Fig. 3C), eight
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(Fig. 3D), and a temperature controlled orbital shaker (Fig. 3E).
The protocol starts with a one-pot sequence of protein dena-
turation and tryptic protein digestion in a 96-well plate. After
trypsin inactivation, glycans are released from peptides using
PNGase F. Starting with 5 mL of serum, the sequence results
in ca. 50 mL reaction volume with a glycan concentration of
ca. 70 mM, of which 20 mL (ca. 1.4 nmol glycans) are used for the
downstream steps. Glycans are first captured on 0.75 mmol
hydrazide on UltraLink Biosupport medium under acid cata-
lysis at elevated temperature (Fig. 2). The solid-supported
reactions were conducted under vigorous shaking conditions
to maintain the solid supports in suspension during reaction
thereby improving the reaction kinetics. Next, contaminants
were removed by a sequence of washing steps with both organic
solvent and aqueous buffers. This was followed by acetyl-
ation of unreacted hydrazide and reagent removal by washing.
Glycans are then released from the solid supports under acid
catalysis at 60 1C. This results in free glycans whose reducing
ends can be labelled with fluorescent dyes such as 2-amino-
benzamide. The labelling reactions are quenched by the addi-
tion of a mixture of acetonitrile and water and the glycans are
thoroughly extracted from the solid supports. The supernatants
are transferred to solid-phase extraction (SPE) cartridges
packed with polymerically bonded diol to capture glycans and
to remove excess reagents. To generate reproducible results,
it was found to be important not to transfer any solid supports
to the SPE cartridges.
Method verification
To verify our protocol, eight serum samples (from pooled native
human serum) were prepared on both the Hamilton Star
workstation as well as manually using the in-gel-block (IGB)
Fig. 1 Sample preparation workflow, consisting of glycoprotein affinity purification, protein denaturation, enzymatic glycan release, glycan immobiliza-
tion on solid-supports, removal of contaminants, glycan release, labelling, solid-phase extraction and UPLC analysis.
Fig. 3 Hamilton liquid handling workstation and safety cabinet (A) deck
view (B), together with its key components: Robotic vacuum manifold
and plate transport tool (C), eight independent pipetting channels with
liquid-level detection and anti-droplet control (D), temperature-controlled
orbital shaker (E).
Fig. 2 Solid-supported hydrazide-mediated sample clean-up. Reducing
end glycans are reacted with solid supported hydrazides to form hydra-
zones, capturing glycans on solid supports. Contaminants such as excess
reagents and buffer salts are removed by filtration. Next, glycans are
released by acid catalysis in the presence of water. Finally, glycans are
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method. The samples were then analyzed on a UPLC system
with fluorescence detection and equipped with a BEH
HILIC glycan column. An overlay chromatogram resulting from
the automated sample preparation method (eight samples),
together with the corresponding peak assignments are shown
in Fig. 4.
Whole native human serum was processed on the liquid
handling workstation as described in the Experimental sec-
tion, followed by glycan analysis by UPLC with fluorescence
detection. The chromatograms depict the N-glycosylation
of human whole serum as well as the corresponding peak
assignments. The overlay of the profiles is shown and the
peaks corresponded to those assigned in Saldova et al.13 The
chromatograms obtained using the robotic method showed
46 integratable peaks, in accordance with previously acquired
data.13 Furthermore, the glycan peak areas were very similar
to those of the IGB method, with only a slight bias towards
smaller glycans in the robotic method (Fig. 5). The coefficients
of variation between the samples prepared with the automated
method were below 10% for all major peaks, i.e. those peaks
with a relative percentage area above 1%. In addition, the
coefficients of variation of the automated method were lower
than those of the IGB method for most glycan peaks (Fig. 6).
Sample cross-over was checked by processing water blanks
alongside serum samples. The UPLC profiles indicated that
sample cross-over was below the UPLC detection limit.
Fig. 5 Comparison of the glycan peak areas from human serum for eight samples between the automated assay and the in-gel-block (IGB) method.
Samples were prepared on the robotic platform or using the IGB method followed by UPLC analysis. GP: glycan peak number.
Fig. 4 Reproducibility of the automated high-throughput platform for the human whole serum N-glycome. The major glycans are highlighted. Human
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Conclusion
Most glycan sample preparation workflows developed to date
are impacted considerably by low sample throughput, lack of
automation and extremely high consumables costs, significantly
hampering the urgently needed progress in glycomics research.
We addressed these key issues and developed a concise, auto-
mated workflow for whole serum N-glycan separation and quanti-
fication. To the best of our knowledge, this is the first low-cost,
automated high-throughput assay for UPLC-based whole serum
glycomics and should enable efficient profiling of glycans for
genome-wide association studies and clinical disease research,
all of which are active research areas in our laboratory.
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